Health Care · Biological Products, (No Diagnostic Substances)

KOD Kodiak Sciences Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 146874872 filings
Russell 2000

KOD at a glance

Kodiak Sciences Inc. (KOD, SEC CIK 1468748) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Kodiak Sciences Inc. (KOD) shares worth $1.6 billion in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by BAKER BROS. ADVISORS LP on November 5, 2026 of 4,703 shares at $98.51 per share.
  • In the last 90 days, KOD insiders reported 86 open-market purchases ($181.3M) and 8 open-market sales ($2.7M) on Form 4, a net purchase of $178.6M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
86 buys · 8 sells
Net +$178.6M
13F holders
29 funds
$1.6B · +1 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes identified: risk factors appear substantially carried forward from the 10-K
  • Clinical efficacy risk: tarcocimab failed primary non-inferiority endpoints in DAZZLE, GLEAM and GLIMMER
  • Regulatory risk: 2024 Loper Bright decision may increase challenges to FDA regulations and create approval uncertainty
  • Market risk: Eylea HD gained FDA approval for RVO in November 2025, intensifying retinal-treatment competition
  • Supply-chain risk: tarcocimab, KSI-501 and KSI-101 rely on single-source suppliers across China, Japan, UK, US and Switzerland

Management Discussion & Analysis

  • No product revenue, compared with no product revenue in the same quarter last year
  • Operating loss $67.1M vs $62.4M YoY, net loss $66.2M vs $61.5M
  • Worst program trend: KSI-101 expenses $11.7M vs $2.6M, up $9.1M YoY
  • Cash $88.7M at September 30, 2026, operating cash used $130.1M through nine months
  • $68.9M net ATM proceeds after quarter-end, $280.4M remaining availability; BLA submission planned for Zenkuda in fourth quarter 2026

AI summary of the KOD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release covers Q3 2026 financial results for quarter ended September 30, 2026
  • Business highlights accompany the quarterly results

Item EX-99.1: Item EX-99.1

  • Zenkuda met DAYBREAK’s primary endpoint with p-value 0.0007, 54% of patients achieving 6-month dosing, supporting planned multi-indication BLA submission in Q4 2026
  • Tabirafusp-ted met vision and anatomical endpoints with p-values 0.0036 and <0.0001, while Phase 3 ALTO enrollment advances in diabetic macular edema
Filed Sep 28, 2026Full analysis →

Item 8.01: Other Events

  • Positive Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted in wet age-related macular degeneration
  • Primary endpoints met for both investigational therapies, supporting potential regulatory submissions

Item EX-99.1: Item EX-99.1

  • Zenkuda met DAYBREAK’s primary endpoint with p=0.0007, showing non-inferior vision gains versus aflibercept in wAMD
  • 54% of Zenkuda patients reached 24-week dosing at year one under strict treat-to-dryness criteria, supporting differentiated durability
Filed Aug 13, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results and business highlights reported for quarter ended June 30, 2026
  • Full financial details and operating developments contained in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q2 2026 net loss $65.6M, or $1.05 per share, versus $54.3M and $1.03 in Q2 2025
  • Cash $125.9M, down from $209.9M at December 31, 2025; management expects funding into 2027

AI summaries of KOD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for KOD

Don't miss the next KOD filing

  • Alerts as it files. A push when KOD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut KOD, by share count.
  • Ask anything. An AI agent that reads every KOD filing and answers with sources.

KOD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
BAKER BROS. ADVISORS LPBuyNov 5, 2026$98.51
BAKER BROS. ADVISORS LPBuyNov 5, 2026$98.51
BAKER BROS. ADVISORS LPBuyNov 4, 2026$98.51
BAKER BROS. ADVISORS LPBuyNov 4, 2026$98.51
Yang TaiyinMOct 23, 2026-
Yang TaiyinMOct 23, 2026$2.35
BORGESON JOHN A.SellOct 21, 2026$87.67
BORGESON JOHN A.MOct 21, 2026$2.49

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$277.3M-$186.8M-$234.4M
Net Income-$260.5M-$176.2M-$230.0M
Balance Sheet
Total Assets-$335.6M$351.5M
Equity$265.8M$150.3M$157.4M
ROE-98.0%-117.2%-146.1%
Per Share
EPS$-4.97$-3.35$-4.32
Cash Flow
Operating CF-$154.2M-$117.3M-$136.0M
CapEx$41.4M$375K$506K

Source: XBRL data in Kodiak Sciences Inc. (KOD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate KOD share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
KOD shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202629$1.59B
Q2 202628$701.5M
Q1 202629$612.3M
Q4 202525$400.4M
Q3 202525$170.3M
Q2 202524$37.7M
Q1 202522$19.3M
Q4 202418$57.0M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 200 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

KOD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 12, 2026Analysis
8-KNov 12, 2026Analysis-
4Nov 6, 2026--
4Oct 26, 2026--
4Oct 23, 2026--
4Sep 30, 2026--
4Sep 30, 2026--
4Sep 30, 2026--
4Sep 29, 2026--
8-KSep 28, 2026Analysis-
SC 13GAug 14, 2026-
8-KAug 13, 2026Analysis-
10-QAug 13, 2026Analysis
4Jul 17, 2026--
4Jul 17, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
4Jun 5, 2026-
8-KJun 4, 2026Analysis
SC 13GMay 15, 2026-
8-KMay 7, 2026Analysis
10-QMay 7, 2026Analysis
SC 13GApr 27, 2026-
4Apr 16, 2026--

Related Health Care companies

All Health Care →

KOD SEC filings: frequently asked questions

Are KOD insiders buying or selling?

In the last 90 days, Kodiak Sciences Inc. (KOD) officers, directors and 10% owners reported 86 open-market purchases worth $181.3 million by 1 insider and 8 open-market sales worth $2.7 million by 1 insider on Form 4, a net purchase of $178.6 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold KOD stock?

As of September 30, 2026, the largest Kodiak Sciences Inc. (KOD) holders among the 13F filers tracked by SignalX were BlackRock ($361.6 million), T. Rowe Price Group ($278.1 million), State Street Corp ($211.3 million), Goldman Sachs Group ($188.7 million), Vanguard Capital Management LLC ($168.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did KOD report in its latest 8-K?

Kodiak Sciences Inc. (KOD) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Q3 2026 financial results for quarter ended September 30, 2026.

What are the latest KOD SEC filings?

Kodiak Sciences Inc. (KOD) filed its latest 10-K annual report on March 31, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 6, 2026.

What is KOD's SEC CIK number?

Kodiak Sciences Inc. (KOD)'s SEC Central Index Key (CIK) is 1468748. EDGAR lists every KOD filing under that number.

Ask anything about KOD

The research agent reads KOD's filings, financials, insider trades and 13F holders, then answers with sources.